A Longitudinal Study of COVID-19 Sequelae and Immunity

STATUS

Recruiting
End date

Dec 31, 2027
participants needed

900
sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Send

Updated on 19 February 2024

See if I qualify

fever

white blood cell count

x-rays

antibody test

pneumonia

pulmonary function tests

leukapheresis

covid-19

chest x-ray

SARS

apheresis

respiratory failure

nasopharyngeal swab

antigen test

nasal swab

asymptomatic infection

pediatric

acute respiratory syndrome (sars)

Summary

Show definitions

Background

COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms. But for others, infection leads to pneumonia, respiratory failure, and, in some cases, death. Researchers want to learn more about any effects that may persist after people recover from COVID-19.

Objective

To learn about any long-term medical problems that people who have recovered from COVID-19 might have, and whether they develop an immune response to SARS-CoV-2 that provides protection against reinfection.

Eligibility

People age 18 and older who have recovered from documented COVID-19 or were in close contact with someone who had COVID-19 but did not get the infection

Design

Participants will be screened over 2 visits. During visit 1, they will answer questions about any symptoms they are having and will be tested for SARS-CoV-2 infection which will involve a nasal swab sample or other FDA approved test. If the test is negative, they will proceed to the second visit, which will include:

Physical examination

Medical history

Mental health interview (which may be recorded if the participant agrees)

Chest x-ray (for recovered COVID-19 participants only)

Blood and urine tests

Pregnancy test (if needed)

Lung function test (for recovered COVID-19 participants only)

6-minute walk test (for recovered COVID-19 participants only)

Questionnaires about their general and mental health

Leukapheresis to collect white blood cells (optional).

Participants will be put into 1 of 2 groups: the COVID-19 group or the close contact group.

Participants will have study visits every 6 months for 3 years. They will repeat some of the screening tests. Participants in the COVID-19 group may have visits more often if they develop symptoms that suggest re-infection with SARS-CoV-2....

Description

Coronavirus disease-2019 (COVID-19) is a newly recognized viral disease primarily involving the respiratory tract. The world is currently experiencing COVID-19 pandemic with a significant portion of those infected developing severe disease manifestations including pneumonia, acute respiratory distress syndrome with respiratory failure, and, in some cases, death. The clinical characteristics and spectrum of disease severity of acute COVID-19 are currently being defined. Since COVID-19 is a new disease, very little is known about possible clinical sequelae that may persist after resolution of the acute infection. In addition, the characteristics of the initial cellular immune and antibody response to SARS-CoV-2 (the virus that causes COVID-19) have not been fully defined and it is not known if the immune responses generated by infection provides long-term protective immunity. The purpose of this study is to establish a longitudinal cohort that has recovered from COVID-19 and characterize the clinical sequelae of acute infection, characterize the immune response to the virus, and follow the evolution of the immune response over time and determine the extent to which natural immunity is protective against re-infection.

Details

Condition	Covid 19
Age	18years - 100years
Clinical Study Identifier	NCT04411147
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'In order to be eligible to participate in this study, all individuals must meet all of the'
	b'following criteria:'
	b'Stated willingness to comply with all study procedures and availability for the'
	b'duration of the study'
	b'Age 18 years or older.'
	b'Ability of participant to understand and the willingness to sign a written informed'
	b'consent document.'
	b'Hemoglobin of 9.0 gm/dl or higher'
	b'Willingness to give consent for the storage of blood samples for research.'
	b'Have a physician or clinic outside NIH to manage underlying medical conditions or'
	b'agreeing to establish care with an outside physician or clinic for any medical'
	b'conditions requiring treatment that may be diagnosed as a result of protocol'
	b'participation.'
	b'COVID-19 Survivor Group'
	b'Documented prior COVID-19 as evidenced by:'
	b'detection of SARS-CoV-2 RNA or antigen in nasopharyngeal swab, sputum or other'
	b'ample source with EUA/approval from the FDA; or'
	b'a positive antibody test using an assay that has received emergency use'
	b'authorization (EUA) from the Food and Drug Administration (FDA) and a history'
	b'clinical manifestation compatible with COVID-19.'
	b'Greater than 6 weeks since onset of COVID-19 symptoms and no fever for at least 1'
	b'week. For individuals with asymptomatic infection, screening will not occur until at'
	b'least 4 weeks after the last positive SARS-CoV-2 PCR or antigen test.'
	b'COVID-19 Close Contact'
	b'Living in the same household as a COVID-19 survivor during the time of illness or,'
	b'being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period'
	b'of time or having direct contact with infectious secretions of a COVID-19 case (e.g.,'
	b'being coughed on).'
	b'No diagnosis of COVID-19 or current symptoms suggestive of COVID-19'
Exclusion Criteria
	b'An individual who meets any of the following criteria will be excluded from participation'
	b'in this study:'
	b'Current abuse of alcohol or other drugs that, in the judgement of the Principal'
	b'Investigator (PI) could interfere with patient compliance.'
	b'Inability to travel to the NIH Clinical Center for study visits'
	b'Any medical or mental health condition that, in the judgement of the PI, would make'
	b'the volunteer unable to participate in the study.'
	b'Positive SARS-CoV-2 PCR at screening visit.'
	b'History of any of the following in the past 14 days: fever > 38.2 degrees Celsius; new'
	b'or worsening respiratory symptoms (e.g. cough, dyspnea).'
	b'Pregnancy'
	b'Pregnant Women will not be enrolled in the protocol. If a woman is pregnant at the time of'
	b'creening she will not be enrolled until the end of her pregnancy because important'
	b'baseline research assessments (e.g. leukapheresis, chest x-ray, pulmonary function testing)'
	b'hould not be done during pregnancy.'
	b'Children will not be included in this study. Due to the rarity of COVID-19 in children (as'
	b'of 4/11/2020 in Maryland, <2% of cases occurred in children), it would not be possible to'
	b'recruit enough children to address the protocol research objectives. In addition, pediatric'
	b'restrictions for the volume of blood permitted to be drawn for research purposes and the'
	b'more than minimal risk of apheresis in children would severely limit the ability to conduct'
	b'the immunologic studies described in this protocol.'
	b'Participation of Employees'
	b'NIH employees may be enrolled in this study as this population meets the study entry'
	b'criteria.'
	b'Neither participation nor refusal to participate as a participant in the research will have'
	b'an effect, either beneficial or adverse, on the participant s employment or position at'
	b'NIH.'

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

fever

white blood cell count

x-rays

antibody test

pneumonia

pulmonary function tests

asymptomatic infection

pediatric

acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

A Longitudinal Study of COVID-19 Sequelae and Immunity